Julia Notter
A5075698019- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- HIV/AIDS drug development and treatment
- Vaccine Coverage and Hesitancy
- Migration, Health and Trauma
- Adolescent Sexual and Reproductive Health
- SARS-CoV-2 and COVID-19 Research
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment
- Reproductive tract infections research
- COVID-19 Clinical Research Studies
- Tuberculosis Research and Epidemiology
- Hepatitis B Virus Studies
- T-cell and B-cell Immunology
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Infectious Diseases and Tuberculosis
- Immune Cell Function and Interaction
- Folate and B Vitamins Research
- Healthcare Systems and Practices
- Long-Term Effects of COVID-19
- Migration, Identity, and Health
- Mental Health and Patient Involvement
- Systemic Lupus Erythematosus Research
University of St. Gallen
2019-2025
University of Basel
2016-2024
University Hospital of Bern
2023-2024
University of Bern
2023-2024
University Hospital of Zurich
2023-2024
University of Zurich
2017-2024
University Hospital Bonn
2023-2024
University of Geneva
2023-2024
University Hospital of Geneva
2023-2024
University Hospital of Basel
2023
Abstract Background Advancements in access to antiretroviral therapy (ART) and human immunodeficiency virus (HIV) care have led a decline AIDS-related deaths among people with HIV (PWH) Switzerland. However, data on the ongoing changes causes of death PWH over past 15 years are scarce. Methods We investigated all reported Swiss Cohort Study between 2005 2022. Causes were categorized using Coding Death protocol. The statistical analysis included demographic stratification identify time trends...
Abstract Background Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people human immunodeficiency virus using a target trial framework, which reduces potential confounding and selection bias. Methods included Swiss HIV Cohort Study participants who were ART-naïve after May 2008, when INSTIs...
The efficacy and tolerability of long-acting cabotegravir rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated an increased virologic failure. This study aims to verify whether drug measured a real-world setting are consistent those previously reported.
Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% acquired anti-IFN-I as they aged (median onset ∼63 years). Once detected, persisted lifelong, and titers increased decades. Individuals developed distinct non-neutralizing autoantibody...
Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although was observed among PWH receiving tenofovir alafenamide (TAF), little known about the potential reversibility after TAF discontinuation. We evaluated and metabolic changes 12 months discontinuation Swiss Cohort Study.
Background & AimsHepatitis B virus (HBV) coinfection is common among people living with HIV (PLWH) and the most important cause of hepatocellular carcinoma (HCC). Whereas risk prediction tools for HCC exist patients HBV monoinfection, they have not been evaluated in PLWH. We performed an external validation PAGE-B HIV/HBV coinfection.MethodsWe included PLWH a positive HBsAg without before starting tenofovir from four European cohorts, estimated predictive performance on occurrence over 15...
We present a case of tabes dorsalis with delayed diagnosis in carpenter who presented VIth cranial nerve palsy, decreased deep tendon reflexes, reduced sense vibration and an unsteady gait. After deterioration symptoms almost complete loss vision due to bilateral optic atrophy, pronounced relative afferent pupillary defect severe gait ataxia, 4 years extensive diagnostic testing ineffective treatments, including several MRIs, genetic analysis eye surgeries, serological was positive for...
Autoantibodies neutralizing type I interferons (IFN-Is; IFNα or IFNω) exacerbate severe viral disease, but specific treatments are unavailable. With footprint profiling, we delineate two dominant IFN-I faces commonly recognized by autoantibody–containing plasmas from aged individuals with HIV-1 and COVID-19. These overlap regions independently essential for engaging the IFNAR1/IFNAR2 heterodimer, efficiently block interaction of both receptor subunits in vitro. In contrast, non-neutralizing...
Coinfections of Mycobacterium tuberculosis (MTB) and human immunodeficiency virus (HIV) impose a substantial global health burden. Patients with MTB infection face heightened risk progression to incident active TB, which preventive therapy can mitigate. Current testing methods often fail identify individuals who subsequently develop TB. We developed random forest models predict TB using patients' medical data at HIV-1 diagnosis. Training our model involved utilizing clinical routinely...
Abstract In this prospective cohort of 1,012 Swiss hospital employees, 3 different assays were used to screen serum for SARS-CoV-2 antibodies. Seropositivity was 1%; the positive predictive values lateral-flow immunoassay 64% (IgG) and 13% (IgM). History fever myalgia most effectively differentiated seropositive seronegative participants.
Abstract Background Next-generation sequencing (NGS) is gradually replacing Sanger (SS) as the primary method for HIV genotypic resistance testing. However, there are limited systematic data on comparability of these methods in a clinical setting presence low-abundance drug mutations (DRMs) and their dependency variant-calling thresholds. Methods To compare HIV-DRMs detected by SS NGS, we included participants enrolled Swiss Cohort Study (SHCS) with NGS sequences available sample collection...
Abstract Background People with human immunodeficiency virus type 1 (HIV-1) (PWH) are frequently coinfected Mycobacterium tuberculosis (MTB) and at risk for progressing from asymptomatic latent TB infection (LTBI) to active (TB). LTBI testing preventive treatment (TB specific prevention) recommended, but its efficacy in low transmission settings is unclear. Methods We included PWH enrolled 1988 2022 the Swiss HIV Cohort study (SHCS). The outcome, incident TB, was defined as ≥6 months after...
Changes in mental and sexual health among men having sex with (MSM) due to the SARS-CoV-2 pandemic remain unclear.Design: Longitudinal analysis of an ongoing, multicentre, pre-exposure prophylaxis (PrEP) cohort (NCT03893188) Switzerland. Participants: HIV-negative MSM aged ≥18 who completed at least one questionnaire before after start pandemic. Outcomes: Primary: health, defined as anxiety depression scores assessed by Patient Health Questionnaire-4. Secondary: behaviour, well-being, PrEP...
Sexually transmitted infections (STIs) are common among people with human immunodeficiency virus (PWH), but there limited data about risk factors and incidence of STIs in large, representative cohort studies. We assessed reported by treating physicians within the Swiss HIV Cohort Study (SHCS). demographic, clinical, behavioral characteristics were prospectively collected at 6-month follow-up visits between October 2017 November 2019. used multilevel Poisson regression to assess rate ratios...
Abstract Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response third dose Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 (98.1% CI, 95.9%–100.0%]) individuals with different levels immunosuppression (difference, −2.8% −6.8% 1.3%]).
ABSTRACT Pre-existing autoantibodies (autoAbs) neutralizing type I interferons (IFN-Is: IFNα, IFNβ, IFNω) have recently been described as significant contributors to the severity of viral infectious diseases. Here, we explore development and consequences anti-IFN-I autoAbs at high-resolution using retrospective samples data from 1876 well-treated individuals >65 years age enrolled in Swiss HIV Cohort Study, a nationwide, longitudinal cohort with up 35 follow-up. Approximately 1.9%...
HIV-1 RNA genetic diversity predicts time since infection, which is important for clinical care and research. It unclear, however, whether proviral DNA sampled under suppressive antiretroviral therapy can be used this purpose. We tested from next-generation sequencing infection recency in 221 people with known time. Proviral was significantly associated (P < 5×10-7, R2 up to 25%) predictive of treatment initiation during recent (area the curve-receiver operating characteristic 0.85). This...
Abstract Background Although sex hormones are recognized to induce immune variations, the effect of hormonal therapy use on immunity is only poorly understood. Here, we quantified how affects HIV‐1 markers in cis women (CW) and trans non‐binary people (TNBP) with HIV. Methods We considered CD4, CD8 lymphocyte measurements from men (CM), CW TNBP Swiss HIV Cohort Study. modelled using linear mixed‐effects models an interaction between ‘gender’ (CW, TNBP) ‘hormonal use’ (yes/no). Models were...
The aim of the study was to assess feasibility a national pre-exposure prophylaxis (PrEP) programme using smartphone-compatible data collection.This multicentre cohort (NCT03893188) enrolling individuals interested in PrEP Switzerland. All centres participate SwissPrEPared programme, which uses collection. Feasibility assessed after had enrolled at least one participant. Participants were HIV-negative presenting for counselling. Outcomes participation (number enrolled/number eligible),...
Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure response. However, this has not been thoroughly evaluated given that obese PWH are underrepresented clinical trials. We performed virtual trials using physiologically based pharmacokinetic (PBPK) modelling combined observed data to provide ARV dosing guidance individuals.
Abstract Objectives Our objective was to obtain long‐term data on the incidence of sexually transmitted infections (STIs) and their association with behavioural factors after widespread pre‐exposure prophylaxis (PrEP) implementation. Methods This a time‐to‐event analysis national PrEP cohort in Switzerland (SwissPrEPared study). Participants were people without HIV interested taking at least two STI screening visits. Primary outcomes rate gonorrhoea, chlamydia, syphilis. The between...
Abstract Background Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of Swiss HIV Cohort Study (SHCS) Transplant (STCS) following bivalent mRNA vaccination. Methods Eligible SHCS STCS participants received approved SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2)...